FILING ANALYSIS · THURSDAY, NOVEMBER 12
DiaMedica Therapeutics Inc. DMAC — 8-K: Results of Operations and Financial Condition
neutral
The company announced completion of enrollment in the first two cohorts of its Phase 2 early-onset fetal growth restriction trial and surpassed the 200-participant enrollment threshold for the ReMEDy2 Phase 2/3 acute ischemic stroke trial, but no quantified financial surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →